Zhejiang CONBA Pharmaceutical Co.,Ltd.: history, ownership, mission, how it works & makes money

From its modest origins as Lanxi Yunshan Pharmaceutical Factory in 1969 to a listed powerhouse on the Shanghai Stock Exchange under ticker 600572 since 2004, Zhejiang CONBA Pharmaceutical Co., Ltd. has grown into the largest traditional Chinese medicine enterprise in Zhejiang and one of the top 10 in China, blending state control-with the Zhejiang SASAC holding a 20.85% stake alongside another 20.85% state-owned holding-and private investment such as CONBA Group's 8.51% and former chairman Hu Jiqiang's 5.20% stakes; its vertically integrated model spans R&D, GMP- and GACP-certified production bases in Jiangxi, Yunnan and Inner Mongolia, a workforce of over 8,000, and diversified product lines from tablets and injections to modern phytomedicines and health consumer goods that generated 580 million yuan in 2023, while core herbal medicine revenue grew 26.79% year-on-year that same year-recent corporate moves include a June 2025 strategic supply agreement between Zhejiang Jinhua CONBA Bio-Pharm and EVA Pharma and an August 2025 reduction by Yuanzhong Biotech of 5.7591 million shares (≈0.228% of total share capital), underscoring active shareholder management as the company pursues green, innovation-driven expansion.

Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS): Intro

• Founded in 1969 as Lanxi Yunshan Pharmaceutical Factory; rebranded in October 1999 to Zhejiang CONBA Pharmaceutical Co.,Ltd.
• Listed on the Shanghai Stock Exchange in 2004 under ticker 600572.
• 2023: achieved a 26.79% year-on-year revenue growth in Chinese herbal medicine and decoction pieces.
• June 2025: Zhejiang Jinhua CONBA Bio-Pharm signed a strategic supply agreement with EVA Pharma to bolster global supply capabilities.
• August 2025: Yuanzhong Biotech Co., Ltd. reduced holdings by 5.7591 million shares (0.228% of total share capital), reflecting active shareholder turnover.

• Chinese herbal medicine & decoction pieces: cultivation, processing, packaged decoctions - a high-growth revenue driver (26.79% YoY growth in 2023 reported for this segment).
• Finished-dosage pharmaceuticals: prescription and OTC products sold domestically through hospitals, pharmacies and distributors.
• Active Pharmaceutical Ingredients (APIs) and intermediates: sold in bulk to other drug manufacturers and internal use.
• Contract manufacturing & supply agreements: outsourced production and strategic partnerships (e.g., June 2025 EVA Pharma deal) to capture export and international procurement opportunities.
• R&D and product pipeline commercialization: new TCM-derived products and formulation upgrades feeding longer-term revenue streams and margin uplift.

• Product mix: margins vary - herbal/decoction pieces typically higher unit margins and volume growth; APIs may be lower margin but steady cash flow.
• Channel mix: hospital tenders and institutional sales drive large-volume contracts; retail pharmacies and e-commerce add margin diversity.
• Scale & integration: upstream raw-material control (herb cultivation/processing) reduces supply risk and input cost volatility, improving gross margin.
• M&A, strategic supply agreements and equity movements: expand market access and optimize capital structure - evidenced by the EVA Pharma agreement (June 2025) and shareholder activity in Aug 2025.

• Manufacturing: multiple production sites for decoction pieces, finished dosage forms and APIs to satisfy domestic and export demand.
• Supply-chain partnerships: strategic supply contracts (e.g., EVA Pharma) to place CONBA as a reliable supplier in global channels.
• Quality & compliance: regulated by Chinese GMP and export-oriented quality systems to meet overseas buyer requirements.

• Ticker: 600572.SS (Shanghai Stock Exchange).
• Recent notable share movement: Yuanzhong Biotech's divestment of 5.7591M shares equals 0.228% of total share capital (Aug 2025).
• Implied total outstanding shares (from the 0.228% figure): ~2.525 billion shares.

Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS): History

• Founded as a regional TCM manufacturer; grew through vertical integration of R&D, production and branded OTC distribution.
• Listed on the Shanghai Stock Exchange under ticker 600572, providing market liquidity and capital access.
• Combination of state ownership and private investors has shaped strategic direction and governance.

• Zhejiang State-owned Assets Supervision and Administration Commission - 20.85% (state control).
• Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. (a wholly-owned subsidiary of Zhejiang International Business Group Co., Ltd.) - 20.85% (state affiliation).
• CONBA Group Co., Ltd. - 8.51%.
• Hu Jiqiang (former chairman) - 5.20%.
• Yuanzhong Biotech Co., Ltd. reduced holdings by 5,759,100 shares (0.228% of total share capital) in August 2025, reflecting active portfolio adjustments.
• Public float and institutional/private investors fill the remainder, balancing state oversight with market participation.

• Product portfolio: topical pharmaceuticals, OTC consumer-health products, TCM formulations and active pharmaceutical ingredients - revenues from domestic sales, exports and licensing.
• Channels: hospital procurement for prescription/clinical products, retail pharmacies and e-commerce for OTC and consumer brands, and B2B supply of raw materials to other manufacturers.
• Value drivers: branded recognition in TCM/OTC, scale manufacturing, R&D pipeline for higher-margin prescription and proprietary formulations, and state-supported market access through shareholder links.

Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS): Ownership Structure

• Mission: Advance modern herbal medicine development and application to supply safe, effective products acceptable to international markets.
• Values: Patient-centric care, integrity in manufacturing, innovation in R&D, and environmental responsibility.
• Strategic priorities: Core-business consolidation, internationalization of products, and high-quality manufacturing practices.

• Product lines: prescription TCM formulations, OTC TCM products, proprietary herbal extracts, and APIs for TCM production.
• Revenue model: manufacturing and sale of finished pharmaceutical products, contract manufacturing, licensing of formulations, and export sales to international markets.
• R&D-driven monetization: new product approvals and lifecycle management of legacy TCM brands to sustain margin and market share.

• Major controlling shareholder: Zhejiang Conba Group (state-linked holding) - significant block holding that provides strategic direction and links to provincial industrial policy.
• Other institutional shareholders: mix of domestic asset managers, mutual funds, and select foreign institutional investors holding the free-float shares listed on the Shanghai Stock Exchange (600572.SS).
• Public float: sufficient to maintain active trading on the A-share market with governance subject to listing rules and state regulatory oversight.

• Adheres to national environmental protection laws and standards; targets for green, low-carbon manufacturing and waste reduction embedded in production planning.
• Quality and safety: emphasizes high-quality reliable manufacturing practices to meet both domestic regulatory requirements and export market standards.

Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS): Mission and Values

• Vertical integration: in‑house R&D → pilot plants → full-scale production → sales & distribution.
• Raw material control: GACP planting bases to secure botanical inputs and ensure traceability.
• Quality & compliance: multiple international and domestic certifications for manufacturing and environmental management.

• Production bases located in Jiangxi, Yunnan and Inner Mongolia, plus a modern GMP herbal industrial park in Lanxi.
• Over 8,000 employees across research, cultivation, production and commercial operations, supporting robust manufacturing capacity and distribution.
• Nationwide medicine production lines-all designed to meet Good Manufacturing Practice (GMP) standards.

• GMP (Good Manufacturing Practice)
• CEP (Certificate of Suitability of Monographs of the European Pharmacopoeia)
• GEP (Good Agricultural and Collection Practice)
• Kosher and Halal certifications for selected product lines
• ISO9001 (Quality Management) and ISO14001 (Environmental Management)

• Finished pharmaceutical products (prescription & OTC) - core revenue source driven by branded formulations and TCM products.
• Bulk botanical extracts and intermediates sold to industry partners and exporters.
• Contract manufacturing and private-label production leveraging GMP facilities.
• Licensing, technology transfer, and collaborative R&D agreements.

• Employee base: >8,000 staff across R&D, cultivation, production and sales.
• Geographic production footprint: Jiangxi, Yunnan, Inner Mongolia + Lanxi herbal industrial park (GMP).
• Certification coverage: GMP, CEP, GEP, Kosher, Halal, ISO9001, ISO14001 - supporting domestic and export market access.

• End‑to‑end control of herb supply (GACP) reduces raw-material volatility and improves gross margins.
• Multiple GMP production sites increase throughput and lower per‑unit manufacturing cost at scale.
• Certifications (CEP, Kosher, Halal, ISO) open premium export markets and institutional procurement channels.
• In‑house R&D accelerates product lifecycle and enables differentiated formulations with higher margins.

Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS): How It Works

• Mission: develop effective, safe and accessible TCM and phytomedicine products while modernizing production and R&D to meet both domestic and export market demand.
• Strategic priorities: brand-driven OTC and prescription portfolios, vertical integration from raw herb sourcing to finished dosage forms, and science-and-technology-led reform as endorsed by the State Council.

• Selected as a 'Sci‑Tech Reform Demonstration Enterprise' under the State‑owned Enterprise Reform initiative of the State Council.
• Recognized as a 'model enterprise for scientific reform' of state‑owned enterprises by the State Council.

• R&D: TCM formula modernization, extraction and standardization of botanical actives, clinical trials for efficacy/safety, and formulation science for diverse dosage forms.
• Manufacturing: GMP-certified facilities producing tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye/nasal/ear drops and ointments.
• Supply chain: vertical sourcing of herbal raw materials, centralized quality control, contract manufacturing for some partners, and distribution via hospital, pharmacy chain, e-commerce and cross-border channels.
• Marketing & brands: branded OTC and Rx products supported by medical promotion, consumer advertising and channel partnerships.

• Product sales: core revenue from sales of TCM preparations, modern phytomedicines and chemical drugs across multiple dosage forms and therapeutic areas.
• Brand-driven OTC income: established brands (see table) generate recurring retail and pharmacy sales and support higher gross margins on consumer goods.
• Institutional channels: hospitals and clinics for prescription and injection products; tenders and institutional procurement add volume for select products.
• Diversification: featured health consumer goods (functional/OTC consumer products) provide a fast-growing non-prescription revenue stream - in 2023 this segment achieved 580,000,000 yuan.
• Licensing/contract manufacturing: technology transfer, co-development and third‑party manufacturing contracts supplement product sales revenue.

• Scale and product mix: volume sales in high-volume OTC tablets/capsules plus higher-value prescription/phytomedicine products drive blended margins.
• Brand premium: long-standing TCM brands enable price resilience in competitive OTC channels.
• Channel mix: pharmacy chains and e‑commerce improve retail reach; hospital procurement supports prescription/injection volumes.
• R&D and reform incentives: state-backed science-and-technology reform status supports accelerated product development and potential access to public funding or preferential programs.

• Listed ticker: 600572.SS (Shanghai) - public disclosures provide periodic revenue, profit and segment data in annual/quarter reports.
• Market presence: combination of established branded TCM products and growing consumer health goods broadens revenue base and reduces concentration risk.
• Operational focus: continuing modernization of manufacturing and evidence-based R&D to penetrate clinical and export markets.

Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS): How It Makes Money

• Core product sales: branded TCM finished dosage forms (OTC and hospital channels) accounting for the bulk of revenue.
• Contract manufacturing and bulk extracts: supplying intermediates and finished products to domestic and export customers.
• Export and international partnerships: strategic supply agreements (e.g., June 2025 strategic supply pact between Zhejiang Jinhua CONBA Bio‑Pharm and EVA Pharma) to expand foreign sales and secure global supply chains.
• Value‑added services: clinical research, technology transfer, and proprietary modern herbal formulations aimed at international regulatory acceptance.
• Sustainability and efficiency gains: green development initiatives reduce energy and waste costs, supporting margins and regulatory compliance.

• Revenue drivers: branded product growth, export contracts, and toll manufacturing; diversification into modern herbal medicine raises addressable markets abroad.
• Cost and margin levers: scale economies in extract production, supply‑chain partnerships (e.g., EVA Pharma agreement), and ongoing green efficiency projects.
• Risk/Opportunity: regulatory acceptance in international markets and successful modernization of TCM formulations will determine long‑term growth trajectory.